Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.37 |
| ▸ | CNR2 | P34972 | 15/20 | 0.37 |
| ▸ | GPR18 | Q14330 | 3/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3072179 | 0.97 | CNR1 (0.39) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL3090860 | 0.96 | CNR2 (0.37) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL3078801 | 0.92 | CNR1 (0.37) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL258641 | 0.92 | CNR1 (0.41) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL3067221 | 0.91 | NPC1 (0.43) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL673359 | 0.89 | CNR1 (0.40) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL551721 | 0.89 | HSPA5 (0.45) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL22289027 | 0.88 | CNR1 (0.42) | CNR1CNR2GPR18GPR55NPC1 | |
| Bisoctrizole SCHEMBL5994398 | 0.87 | CNR2 (0.39) | CNR1CNR2GPR18GPR55NPC1 | |
| SCHEMBL3075839 | 0.87 | NPC1 (0.38) | NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106470973-B | Small molecule L FA-1 inhibitor | 阿罗赛特制药公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-109422765-A | C class beta-lactamase inhibitor and its preparation method and application | 香港理工大学深圳研究院 | 2019-03-05 | — | — | CN | disclosed |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| CN-108778273-A | bicyclic aryl monocyclic β -lactam compounds and methods of use thereof for treating bacterial infections | 默沙东公司 | 2018-11-09 | — | — | CN | disclosed |
| US-10077238-B2 | Small molecule LFA-1 inhibitors | ALLOCYTE PHARMACEUTICALS AG (CH) | 2018-09-18 | — | — | US | disclosed |
| CN-104910329-B | A kind of polar cyclic olefin copolymer and preparation method thereof | 天津大学 | 2017-08-22 | — | — | CN | disclosed |
| US-20170121284-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| EP-3154941-A1 | SMALL MOLECULE LFA-1 INHIBITORS | AlloCyte Pharmaceuticals AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| CN-106470973-A | Small molecule lfa-1 inhibitors | 阿罗赛特制药公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-103958521-B | Pyrimidin-4-one derivatives and their use in the treatment, alleviation or prevention of viral diseases | 弗·哈夫曼-拉罗切有限公司 | 2016-10-19 | — | — | CN | disclosed |
| EP-0847997-A1 | Benzotriazolyl-alkylene bisphenol compounds, process for their preparation, and stabilized organic materials containing them | Johoku Chemical Co., Ltd. (JP) | 1998-06-17 | — | — | EP | disclosed |
| US-5703246-A | REACTING AN ORGANOMETALLIC COMPOUND WITH ORGANOSULFUR COMPOUND | ZENECA LIMITED (GB) | 1997-12-30 | — | — | US | disclosed |
| WO-1997032883-A1 | AZOLOBENZAZEPINE DERIVATIVES AS NEUROLOGICALLY ACTIVE AGENTS | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |
| EP-0724569-A1 | PROCESS FOR THE PREPARATION OF AN OXIRANE, AZIRIDINE OR CYCLOPROPANE | ZENECA LIMITED (GB) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995011230-A1 | PROCESS FOR THE PREPARATION OF AN OXIRANE, AZIRIDINE OR CYCLOPROPANE | ZENECA LIMITED (GB) | 1995-04-27 | — | — | WO | disclosed |
| US-4235917-A | N-Alkyl-N-acyl derivatives of thienamycin | MERCK & CO., INC. (US) | 1980-11-25 | — | — | US | disclosed |
| US-4235920-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1980-11-25 | — | — | US | disclosed |
| US-4181733-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1980-01-01 | — | — | US | disclosed |
| US-4172144-A | Schiff's base derivatives of thienamycin | MERCK & CO., INC. (US) | 1979-10-23 | — | — | US | disclosed |
| US-4150145-A | ANTIBIOTIC, BACTERICIDES | MERCK & CO., INC. (US) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077238-B2 | Small molecule LFA-1 inhibitors | ICAM1, VCAM1, ITGB1 | CNR1 4142/4885CNR2 4744/4885GPR18 4132/4885 |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ICAM1, VCAM1, ITGB1 | CNR1 4142/4885CNR2 4744/4885GPR18 4132/4885 |
| US-20170121284-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ICAM1, VCAM1, ITGB1 | CNR1 4142/4885CNR2 4744/4885GPR18 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.